Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00843310 · ClinicalTrials.gov registry record · Phase 2
Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma
A Phase 2 study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT00843310 is a Phase 2 study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 8 participants.
The verdict
NCT00843310, a Phase 2 study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study is to determine whether addition of Revlimid to standard therapy will increase overall and complete response rates compared to historical standard frontline therapy and whether this combination treatment has fewer side effects than similar combination induction treatment.
Interventions
- DRUG Melphalan
- DRUG Dexamethasone
- DRUG Lenalidomide (Revlimid)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2008-11 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00843310
The ClinicalTrials.gov registry entry for NCT00843310 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Melphalan is the first listed.
NCT00843310 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00843310 about?
NCT00843310 is a clinical study titled "Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma". This study is to determine whether addition of Revlimid to standard therapy will increase overall and complete response rates compared to historical standard frontline therapy and whether this combination treatment has fewer side effects than similar combination induction treatment.
What is the current status of trial NCT00843310?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2008-11. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00843310?
The interventions under investigation include: Melphalan (DRUG), Dexamethasone (DRUG), Lenalidomide (Revlimid) (DRUG).
Who is sponsoring clinical trial NCT00843310?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.